Edition:
United States

Chimerix Inc (CMRX.OQ)

CMRX.OQ on NASDAQ Stock Exchange Global Market

4.70USD
4:00pm EDT
Change (% chg)

$0.08 (+1.73%)
Prev Close
$4.62
Open
$4.60
Day's High
$4.73
Day's Low
$4.60
Volume
32,384
Avg. Vol
46,951
52-wk High
$5.93
52-wk Low
$4.18

Chart for

About

Chimerix, Inc. is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses,... (more)

Overall

Beta: 1.34
Market Cap(Mil.): $219.19
Shares Outstanding(Mil.): 47.75
Dividend: --
Yield (%): --

Financials

  CMRX.OQ Industry Sector
P/E (TTM): -- 241.68 34.14
EPS (TTM): -1.55 -- --
ROI: -31.11 -5.91 13.17
ROE: -31.15 -7.75 15.14

BRIEF-Chimerix Announces Martha J. Demski As Board Chair

* CHIMERIX ANNOUNCES MARTHA J. DEMSKI AS BOARD CHAIR; APPOINTS NEW MEMBERS TO BOARD OF DIRECTORS

Mar 29 2018

BRIEF-Chimerix Announces Q4 Loss Per Share $0.41

* CHIMERIX ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 01 2018

BRIEF-Arrowmark Colorado Holdings Llc Reports 5.7 PCT Passive Stake In Chimerix As Of Dec 31, 2017

* ARROWMARK COLORADO HOLDINGS LLC REPORTS 5.7 PERCENT PASSIVE STAKE IN CHIMERIX INC AS OF DECEMBER 31, 2017 - SEC FILING‍​ Source text - (http://bit.ly/2EeZ3kp) Further company coverage:

Feb 09 2018

BRIEF-Chimerix Initiates Adapt Study For Oral Brincidofovir

* CHIMERIX INITIATES ADAPT STUDY FOR ORAL BRINCIDOFOVIR AND ADVANCES IV BRINCIDOFOVIR TO PATIENT STUDIES Source text for Eikon: Further company coverage:

Jan 05 2018

Earnings vs. Estimates